Imperial College London

DrSanjayPopat

Faculty of MedicineNational Heart & Lung Institute

Reader in Cancer Medicine
 
 
 
//

Contact

 

+44 (0)20 7808 2132s.popat Website

 
 
//

Location

 

Royal Marsden HospitalThe Royal Marsden Hospital

//

Summary

 

Publications

Citation

BibTex format

@inproceedings{Tiseo:2022:10.1016/j.annonc.2022.02.038,
author = {Tiseo, M and Popat, S and Kim, HR and Ahn, M-J and Yang, JC and Han, J-Y and Hochmair, MJ and Lee, KH and Delmonte, A and Garcia, Campelo MR and Kim, D-W and Griesinger, F and Felip, E and Califano, R and Spira, AI and Gettinger, SN and Lin, HM and Liu, Y and Vranceanu, F and Camidge, R},
doi = {10.1016/j.annonc.2022.02.038},
pages = {S44--S45},
publisher = {ELSEVIER},
title = {Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK plus non-small cell lung cancer (NSCLC): ALTA-1L final results},
url = {http://dx.doi.org/10.1016/j.annonc.2022.02.038},
year = {2022}
}

RIS format (EndNote, RefMan)

TY  - CPAPER
AU - Tiseo,M
AU - Popat,S
AU - Kim,HR
AU - Ahn,M-J
AU - Yang,JC
AU - Han,J-Y
AU - Hochmair,MJ
AU - Lee,KH
AU - Delmonte,A
AU - Garcia,Campelo MR
AU - Kim,D-W
AU - Griesinger,F
AU - Felip,E
AU - Califano,R
AU - Spira,AI
AU - Gettinger,SN
AU - Lin,HM
AU - Liu,Y
AU - Vranceanu,F
AU - Camidge,R
DO - 10.1016/j.annonc.2022.02.038
EP - 45
PB - ELSEVIER
PY - 2022///
SN - 0923-7534
SP - 44
TI - Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK plus non-small cell lung cancer (NSCLC): ALTA-1L final results
UR - http://dx.doi.org/10.1016/j.annonc.2022.02.038
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000778453100030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
ER -